(Press-News.org) PHILADELPHIA – Insulin resistance in the brain precedes and contributes to cognitive decline above and beyond other known causes of Alzheimer's disease, according to a new study by researchers from the Perelman School of Medicine at the University of Pennsylvania. Insulin is an important hormone in many bodily functions, including the health of brain cells. The team identified extensive abnormalities in the activity of two major signaling pathways for insulin and insulin-like growth factor in non-diabetic people with Alzheimer's disease. These pathways could be targeted with new or existing medicines to potentially help resensitize the brain to insulin and possibly slow down or even improve cognitive decline.
This is the first study to directly demonstrate that insulin resistance occurs in the brains of people with Alzheimer's disease. The study is now online in the Journal of Clinical Investigation.
"Our research clearly shows that the brain's ability to respond to insulin, which is important for normal brain function, is going offline at some point. Insulin in the brain not only modulates glucose uptake, but also promotes the health of brain cells – their growth, survival, remodeling, and normal functioning. We believe that brain insulin resistance may be an important contributor to the cognitive decline associated with Alzheimer's disease," said senior author, Steven E. Arnold, MD, professor of Psychiatry and Neurology. Arnold is also the director of the Penn Memory Center, a National Institute on Aging-designated Alzheimer's Disease Core Center. "If we can prevent brain insulin resistance from occurring, or re-sensitize brain cells to insulin with any of the currently available insulin-sensitizing diabetes medicines, we may be able to slow down, prevent, or perhaps even improve cognitive decline.
The risk of developing Alzheimer's disease is increased by 50 percent in people with diabetes. Type 2 diabetes is due to insulin resistance and accounts for 90 percent of all diabetes. The defining clinical feature of Type 2 diabetes (and Type 1 "juvenile" diabetes) is hyperglycemia - high levels of sugar in the blood – but there is no evidence that the brain in Alzheimer's is hyperglycemic. Insulin acts differently in the brain than in the rest of the body. Researchers found that insulin resistance of the brain occurs in Alzheimer's disease independent of whether someone has diabetes, by excluding people with a history of diabetes from this study.
The investigators used samples of postmortem brain tissue from non-diabetics who had died with Alzheimer's disease, stimulated the tissue with insulin, and measured how much the insulin activated various proteins in the insulin-signaling pathways. There was less insulin activation in Alzheimer's cases than in tissue from people who had died without brain disease. Other proteins linked to insulin action in the brain were abnormal in Alzheimer's disease samples. These abnormalities were highly correlated with episodic memory and other cognitive disabilities in the Alzheimer's disease patients.
In tissue from people with Alzheimer's disease and mild cognitive impairment (MCI), researchers found that changes to a protein called insulin receptor substrate-1 (IRS-1 pS636/639 and pS616) in brain cells were linked to the severity of memory impairments regardless of age, sex, diabetes history, or apolipoprotein E (APOE) gene status. Levels of IRS-1 were also significantly associated with, but not likely to affect, the presence of amyloid beta plaques and neurofibrillary tangles, the signature markers of Alzheimer's disease. This suggests that insulin resistance contributes to cognitive decline independent of the classical pathology of Alzheimer's disease.
Researchers noted that three insulin-sensitizing medicines are already approved by the FDA for treatment of diabetes. These drugs readily cross the blood-brain barrier and may have therapeutic potential to correct insulin resistance in Alzheimer's disease and MCI. "Clinical trials would need to be conducted to determine the impact the drugs have on Alzheimer's disease and MCI in non-diabetic patients," said Dr. Arnold.
###The study's lead author, Konrad Talbot, PhD, is a Research Assistant Professor in Penn's Psychiatry department and co-lead author, Hoau-Yan Wang, Ph.D. is an Associate Medical Professor of
Physiology and Pharmacology at the City University of New York. Along with Drs .Talbot and Arnold, the Perelman School of Medicine research team from Penn includes: Hala Kazi, Li-Ying Han, Robert L. Fuino, Krista R. Kawaguchi, Andrew J. Samoyed, from Psychiatry; Bryan A. Wolf (from Children's Hospital of Philadelphia) and John Q. Trojanowski, both from Penn's Department of Pathology and Laboratory Medicine. In addition, other researchers from the City University of New York Medical School and the Rush Alzheimer's Disease Center from Rush University Medical Center contributed equally to this work.
The study was supported by the Alzheimer's Association (a T.L.L. Temple Foundation Discovery Award), the National Institute on Aging (at Penn: RO1 AG15819, P30 AG10124, at Rush: P30 AG10161) and the Allen H and Selma W. Berkman Charitable Trust. The study would not have been possible without all the patients and families that contributed to this study, as well as the volunteers in the Rush Religious Order Study.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine is currently ranked #2 in U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $479.3 million awarded in the 2011 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top 10 hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital – the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2011, Penn Medicine provided $854 million to benefit our community.
Brain insulin resistance contributes to cognitive decline in Alzheimer's disease
2012-03-26
ELSE PRESS RELEASES FROM THIS DATE:
Research sheds new light on extra help for smokers trying to quit
2012-03-26
A major research trial to test whether extra support for smokers calling an NHS quitline - on top of what is already offered by the service - has found the additional help does not improve success rates for quitting the habit.
The pilot scheme offered smokers additional help in the form of free nicotine patches and extra telephone counselling from the English National Quitline. The Department of Health and UK Centre for Tobacco Control Studies (UKCTCS)-funded study led by The University of Nottingham's UK Centre for Tobacco Control Studies has just been published in the ...
Non-narcotic pain medication is safe and effective after sinus surgery
2012-03-26
MAYWOOD, Il. -- Patients who have undergone sinus surgery can safely take an alternative pain medication that does not cause the side effects of narcotics such as fentanyl and Vicodin, a Loyola University Health System study has found.
The alternative medication is ketorolac (brand name, Toradol). It is in the same class of nonsteroidal anti-inflammatory drugs as Advil and Aleve. Ketorolac does not cause the side effects that narcotic drugs cause, such as itching, nausea, vomiting, constipation and drowsiness, said Kevin Welch, MD, corresponding author of the study, published ...
Identifying acute myeloid leukemia gene mutations may indicate risk, best treatment
2012-03-26
TAMPA, Fla. – An international group of researchers, including those from Moffitt Cancer Center in Tampa, Fla., have published a paper in the March 14 issue of the New England Journal of Medicine reviewing the results of a study that analyzed mutations in 18 genes of 398 patients who had acute myeloid leukemia (AML). They found that several mutated genes predicted improved outcomes when patients with certain gene mutations were given high-dose induction chemotherapy. Their findings suggest that mutational profiling could potentially be used for both risk stratification ...
Marine forensics expert Richard Woytowich seeks to vindicate Titanic survivors' account
2012-03-26
Brooklyn, NY -- On the eve of the 100th anniversary of the Titanic's sinking, marine forensics expert Richard Woytowich will present a paper re-interpreting the statements made by survivors at the 1912 official inquiries into the disaster.
Woytowich, a professor of computer engineering technology at New York City College of Technology (City Tech), will take into account what engineers and other technologists now know about how the ill-fated passenger liner broke apart on April 15, 1912. He will be presenting his research on April 4, 8 a.m., at the International Marine ...
A new test might facilitate diagnosis and drug development for Alzheimer's disease
2012-03-26
An international team of researchers have developed a new method for measurement of aggregated beta-amyloid – a protein complex believed to cause major nerve cell damage and dysfunction in Alzheimer's disease. The new method might facilitate diagnosis and detection as well as development of drugs directed against aggregated beta-amyloid.
Alzheimer's disease (AD) is the most common cause of memory decline and dementia. According to the Alzheimer World Report 2011, today around 36 million people suffer from Dementia (around 20 - 25 million are Alzheimer's patients). These ...
New ORNL tool developed to assess global freshwater stress
2012-03-26
A new method to make better use of vast amounts of data related to global geography, population and climate may help determine the relative importance of population increases vs. climate change.
While several recent studies suggest that much of the world is likely to experience freshwater shortages as the population increases and temperatures rise, determining the relative impact of each has been difficult. An Oak Ridge National Laboratory paper published in Computers & Geosciences outlines a process that might help.
"Our work establishes a new method to couple geographic ...
'Bed-of-nails' breast implant deters cancer cells
2012-03-26
PROVIDENCE, R.I. [Brown University] -- One in eight women in the United States will develop breast cancer. Of those, many will undergo surgery to remove the tumor and will require some kind of breast reconstruction afterward, often involving implants. Cancer is an elusive target, though, and malignant cells return for as many as one-fifth of women originally diagnosed, according to the American Cancer Society.
Would it be possible to engineer implant materials that might drive down that rate of relapse? Brown University biomedical scientists report some promising advances. ...
Huge hamsters and pint-sized porcupines thrive on islands
2012-03-26
DURHAM, N.C. -- From miniature elephants to monster mice, and even Hobbit-sized humans, size changes in island animals are well-known to science. Biologists have long believed that large animals evolving on islands tend to get smaller, while small animals tend to get bigger, a generalization they call "the island rule."
A new study by researchers at Duke University and the National Evolutionary Synthesis Center in Durham, NC puts that old idea to the test in island and mainland rodents.
"Some of the size changes observed in island animals are pretty dramatic," said ...
Researchers unveil robot jellyfish built on nanotechnology
2012-03-26
Researchers at The University of Texas at Dallas and Virginia Tech have created an undersea vehicle inspired by the common jellyfish that runs on renewable energy and could be used in ocean rescue and surveillance missions.
In a study published this week in Smart Materials and Structures, scientists created a robotic jellyfish, dubbed Robojelly, that feeds off hydrogen and oxygen gases found in water.
"We've created an underwater robot that doesn't need batteries or electricity," said Dr. Yonas Tadesse, assistant professor of mechanical engineering at UT Dallas and ...
Possible causes of sudden onset OCD in kids broadened
2012-03-26
Criteria for a broadened syndrome of acute onset obsessive compulsive disorder (OCD) have been proposed by a National Institutes of Health scientist and her colleagues. The syndrome, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), includes children and teens that suddenly develop on-again/off-again OCD symptoms or abnormal eating behaviors, along with other psychiatric symptoms – without any known cause.
PANS expands on Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcus (PANDAS), which is limited to a subset of cases traceable to ...